The Alzheimer’s Network for Treatment and Diagnostics (ALZ-NET) collects longitudinal data from patients treated with novel FDA approved therapies for Alzheimer’s disease (AD), and tracks patient health outcomes (clinical response and safety), associated with use in real-world settings. ALZ-NET aims to assess the clinical course of individuals from a variety of backgrounds and communities, to achieve representativeness beyond the populations historically enrolled in clinical trials. ALZ-NET is a resource for evidence gathering, information sharing, and education across clinical and research communities, encouraging innovative, inclusive research, and supporting opportunities to improve care.
AIM 1: Establish the necessary network infrastructure:
AIM 2: The registry will develop mechanisms to co-enroll participants in affiliated trials
AIM 3: The registry will collect data to evaluate long term safety, clinical use and outcomes:
AIM 4: Merge and compare ALZ-NET data with existing databases to further understand patient outcomes and resource utilization
AIM 5: Establish and implement infrastructure for sharing of de-identified data, images and biosamples